Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gilead Sciences : Trodelvy Significantly Improved Quality of Life Over Standard of Care in 2L+ Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT Study

09/17/2021 | 08:09am EDT

FOSTER CITY, Calif. - Gilead Sciences, Inc. (Nasdaq: GILD) announced new data from the Phase 3 ASCENT study of Trodelvy (sacituzumab govitecan-hziy) in patients with relapsed or refractory metastatic triple-negative breast cancer (TNBC) who received two or more prior systemic therapies, at least one of them for metastatic disease. In addition to the previously reported overall survival benefit observed with Trodelvy compared with chemotherapy chosen by patients' physicians (11.8 months vs. 6.9 months; HR: 0.51; 95% CI: 0.41-0.62; p

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about GILEAD SCIENCES, INC.
07:56aGILEAD SCIENCES : Presents Long-Term Switch Data Reinforcing Biktarvy as a Treatment Optio..
AQ
10/21GILEAD SCIENCES : Presents Long-Term Switch Data Reinforcing Biktarvy® as a Treatment Opti..
BU
10/21GILEAD SCIENCES : Announces Decision Not to Pursue Marketing Authorization for Descovy for..
AQ
10/20GILEAD SCIENCES : Announces Decision Not to Pursue Marketing Authorization for Descovy® fo..
PU
10/19Atea plunges after COVID-19 treatment fails to help patients in study
RE
10/19GILEAD SCIENCES : to Donate 103,000 Vials of Veklury to Indonesia, Armenia
MT
10/19GILEAD SCIENCES : Announces Veklury® Donations to Help Address the Ongoing COVID-19 Crisis..
BU
10/19GILEAD SCIENCES : U.S. Food and Drug Administration Approves Expanded Indication of Gilead..
AQ
10/18GILEAD SCIENCES : Secures FDA Approval for Expanded Indication of Biktarvy for Treatment o..
MT
10/18GILEAD SCIENCES : U.S. Food and Drug Administration Approves Expanded Indication of Gilead..
BU
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 25 188 M - -
Net income 2021 6 427 M - -
Net Debt 2021 23 041 M - -
P/E ratio 2021 13,4x
Yield 2021 4,20%
Capitalization 84 306 M 84 306 M -
EV / Sales 2021 4,26x
EV / Sales 2022 4,21x
Nbr of Employees 13 600
Free-Float 99,9%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | MarketScreener
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 67,24 $
Average target price 76,35 $
Spread / Average Target 13,5%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.15.41%83 993
BIONTECH SE251.28%69 162
WUXI APPTEC CO., LTD.24.51%65 142
REGENERON PHARMACEUTICALS17.86%59 196
VERTEX PHARMACEUTICALS-20.84%48 536
BEIGENE, LTD.45.24%35 024